Understanding and optimizing the potential public health impact of a gonococcal vaccine

淋病奈瑟氏菌(NGO)是性传播感染(STI)淋病的病原体。 世界范围内的重大公共卫生问题。淋球菌感染的临床结果从无症状到 感染严重后遗症，包括盆腔炎、不良妊娠结局、新生儿 并发症和不孕不育。感染NGO还会增加感染和传播艾滋病毒的风险。这个 淋球菌感染发病率上升和耐多药的NGO超级菌株出现 明确表示迫切需要以疫苗为基础的干预措施。 在这个项目中，我们的总体目标是收集所需的数据，以了解 广泛实施淋病疫苗，以确定哪些信息可能会增加吸收，以及 找出可最大限度减少 淋病流行。 鉴于快速评估和实施淋球菌的能力，这些研究具有非常重要的意义 疫苗一旦可用，是必不可少的。 具体目标是： 目的1：描述具有不同表型的NGO的分布和传播，并确定变异性 在疫苗目标中。 目标2：在不同的人群中，描述对淋病的了解和对风险的看法 以及评估对淋球菌疫苗的接受程度。 目标3：模拟不同疫苗配方和不同目标人群的潜在影响，以指导 淋病疫苗的开发和实施。

Neisseria gonorrhoeae (Ngo), the causative agent of the sexually transmitted infection (STI) gonorrhea, is a major public health problem worldwide. The clinical outcomes of gonococcal infection range from asymptomatic infection to severe sequelae that include pelvic inflammatory disease, adverse pregnancy outcomes, neonatal complications and infertility. Infection with Ngo also increases the risk of acquiring and transmitting HIV. The increasing incidence of gonococcal infection and the emergence of multidrug resistant ‘superbug’ strains of Ngo make it clear that a vaccine-based intervention is urgently needed. In this project our overall goal is to gather the data required to understand any potential barriers to the widespread implementation of a gonococcal vaccine, to determine what information might increase uptake, and to identify the vaccine features and vaccination strategy that will have the maximum impact on reducing the prevalence of gonorrhea. These studies are highly significant given that the ability to rapidly evaluate and implement a gonococcal vaccine, once available, is essential. The specific aims are: AIM 1: Describe the distribution and transmission of Ngo with different phenotypes, and determine variability among vaccine targets. AIM 2: Among various populations, describe understanding of gonococcal disease and perceptions of risk as well as assess acceptance of a gonococcal vaccine. AIM 3: Model the potential impact of different vaccine formulations and different target populations to guide gonococcal vaccine development and implementation.